Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)

Trial Profile

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MUK Seven
  • Most Recent Events

    • 04 Dec 2018 Results evaluating changes in immune cell sub-group composition associated with the addition of cyclophosphamide to pomalidomide in Multiple myeloma patients presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Initial results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top